•  
  •  
 

Abstract

The concurrent use of fluoxetine and risperidone to treat schizophrenia may result in drug interactions. This study aims to analyse the clinical outcomes of fluoxetine-risperidone therapy and the possibility of their interaction in schizophrenic patients. The clinical outcomes are patient status at the time of hospital discharge, the length of hospitalisation and the Positive and Negative Syndrome Scale- Excitement Component (PANSS-EC). This study was conducted prospectively in psychiatric ward of HB Saanin Mental Hospital from May to October 2021 and study subjects were selected using consecutive sampling technique with inclusion criteria. Forty-three patients were eligible for this study. Research data were collected from direct observation and notes from medical records. To provide an overview of the frequency distribution and percentage of the variables evaluated, the data were analysed through descriptive statistics and a chi-square test using SPSS v.22. Symptoms due to risperidone-fluoxetine interaction were found in four patients (10%). The symptoms experienced are categorised as extrapyramidal syndrome (EPS). The results of the clinical outcomes showed that 38 patients (88%) having recovered and five patients (12%) were in remission. The PANSS-EC in male patient (6.24±1.12) was higher than female (5.88±1.12). The length of hospitalization was higher in patient with age 36-45 years (23.72). This study showed no significant relationship between fluoxetine-risperidone interaction on the outcome of therapy (p>0.05). It can be concluded that EPS was found in 10% of schizophrenic patients. However, there was no significant association between EPS due to fluoxetine-risperidone interaction with clinical outcomes.

References

Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLoS ONE, 16(9 September), 6–17. https://doi.org/10.1371/journal.pone.0257129

Andira, S., & Nuralita, N. S. (2018). Pengaruh perbedaan jenis kelamin terhadap simtom depresi pasien skizofrenia di Rumah Sakit Jiwa Prof . Dr . M . Ildrem Kota Medan Sumatera Utara pada Tahun 2017. Buletin Farmatera, 3(2), 97–108.

Arroll, B., Chin, W. Y., Martis, W., Goodyear-Smith, F., Mount, V., Kingsford, D., Humm, S., Blashki, G., & Macgillivray, S. (2016). Antidepressants for treatment of depression in primary care: A systematic review and meta-analysis. Journal of Primary Health Care, 8(4), 325–334. https://doi.org/10.1071/HC16008

Ash, T. M., Brown, E. N., Irvin, A. M., & Abraham, S. P. (2020). Schizoaffective disorder : Implications of social dysfunction. International Journal of Science and Research Methodology, 17(2), 246–259.

Barrett, K., Brooks, H., Boitano, S., & Barman, S. (2010). Ganong’s Review of Medical Physiology (23rd ed.). Mc Graw-Hill Medical. https://doi. org/10.1111/j.1469-8749.1962.tb03197.x

Cahyaningtyas, C., Rahmatini, R., & Sedjahtera, K. (2017). Hubungan lama terapi antipsikotik dengan kadar SGOT dan SGPT pada pasien skizofrenia di RSJ Prof. H.B Sa’anin, Padang Tahun 2013. Jurnal Kesehatan Andalas, 6(1), 128–133. https://doi.org/10.25077/jka. v6i1.658

Cascorbi, I. (2012). Drug interactions-principles, examples and clinical consequences reply. Deutsches Arzteblatt International, 109(33–34), 546–556. https:// doi.org/10.3238/arztebl.2012.0546

Chiappini, S., Mosca, A., Miuli, A., Semeraro, F. M., Mancusi, G., Santovito, M. C., Di Carlo, F., Pettorruso, M., Guirguis, A., Corkery, J. M., Martinotti, G., Schifano, F., & Di Giannantonio, M. (2022). Misuse of anticholinergic medications: A systematic review. Biomedicines, 10(2), 1–27. https://doi.org/10.3390/ biomedicines10020355

Curry, S. H., & Whelpton, R. (2017). Introduction to Drug Disposition and Pharmacokinetics. In S. H. Curry & R. Whelpton (Eds.), Introduction to Drug Disposition and Pharmacokinetics (1st ed., pp. 260–283). John Wiley & Sons, Ltd. https://doi.org/10.1002/9781119261087

Dania, H., Faridah, I. N., Rahmah, K. F., Abdulah, R., Barliana, M. I., & Perwitasari, D. A. (2019). Hubungan pemberian terapi antipsikotik terhadap kejadian efek samping sindrom ekstrapiramidal pada pasien rawat jalan di salah satu Rumah Sakit di Bantul, Yogyakarta. Indonesian Journal of Clinical Pharmacy, 8(1), 19–30. https://doi.org/10.15416/ijcp.2019.8.1.19

Dhanya, T., Gangadhar, R., & Subha, N. (2015). Clinical and economic outcomes of risperidone versus clozapine in the treatment of chronic schizophrenia. International Journal of Basic and Clinical Pharmacology, 4(6), 1080–1085.https://doi.org/10.18203/2319-2003. ijbcp20151335

Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wellls, B. G., & Posey, L. M. (2010). Pharmacotherapy A pathophysiologic approach. In J. T. DiPiro (Ed.), Pharmacotherapy A Pathophysiologic Approach (7th ed.). The McGraw-Hill Companies. https://doi. org/10.5694/j.1326-5377.1989.tb136626.x

Donoghue, J., & Lader, M. (2010). Usage of benzodiazepines: A review. International Journal of Psychiatry in Clinical Practice, 14(2), 78–87. https:// doi.org/10.3109/13651500903447810

Farah, F. H. (2018). Schizophrenia : An overview. Asian Journal of Pharmaceutics, 12(2), 78–87.

Gogtay, N., Vyas, N. S., Testa, R., Wood, S. J., & Pantelis, C. (2011). Age of onset of schizophrenia: Perspectives from structural neuroimaging studies. Schizophrenia Bulletin, 37(3), 504–513. https://doi.org/10.1093/schbul/ sbr030

Handayani, L., Febriani, F., Rahmadanni, A., & Saufi, A. (2017). Faktor risiko kejadian skizofrenia di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (DIY). Humanitas, 13(2), 135. https://doi.org/10.26555/ humanitas.v13i2.6069

Harrow, M., Grossman, L. S., Herbener, E. S., & Davies, E. W. (2000). Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. British Journal of Psychiatry, 177(NOV.), 421–426. https://doi.org/10.1192/bjp.177.5.421

Hasni, D., Ridho, M., & Anissa, M. (2020). Gambaran sindrom ekstrapiramidal pada pasien skizofrenia yang mendapat terapi antipsikotik. Jurnal Kedokteran YARSI, 27(3), 090–094. https://doi.org/10.33476/jky.v27i3.983

Ih, H., Putri, R. A., & Untari, E. K. (2016). Perbedaan jenis terapi antipsikotik terhadap lama rawat inap pasien skizofrenia fase akut di RSJD Sungai Bangkong Pontianak. Indonesian Journal of Clinical Pharmacy, 5(2), 115–122. https://doi.org/10.15416/ ijcp.2016.5.2.115

Kartika, S. D. (2020). Analisis faktor risiko yang mempengaruhi outcome pasien sepsis di Rumah Sakit Umum Pusat Fatmawati. SCIENTIA : Jurnal Farmasi Dan Kesehatan, 10(1), 17–32. https://doi.org/10.36434/ scientia.v10i1.301

Katzung, B.G., Masters, S.B., Trevor, A.J. (2012). Basic & Clinical Pharmacology (12th Editi). McGraw- Hill.

Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. British Medical Bulletin, 114(1), 169–179. https://doi.org/10.1093/bmb/ ldv017

Lorensia, A., & Wijaya, R. I. (2020). Hubungan jumlah obat yang digunakan terhadap risiko terjadinya drugrelated problems pada pasien asma di suatu Rumah Sakit Di Surabaya. Journal of Tropical Pharmacy and Chemistry, 3(3), 232–238.

Madaan, V. (2009). Risperidone: a review of efficacy studies in adolescents with schizophrenia. Drugs of Today (Barcelona, Spain : 1998), 45(1), 55–62. https:// doi.org/10.1358/dot.2009.45.1.1315074

Ministry of Health, Republic of Indonesia. (2019). Profil Kesehatan Indonesia (Vol. 1, Issue 4). https://doi. org/10.1080/09505438809526230

Mowla, A., Dastgheib, S. A., Ebrahimi, A. ., & Pani, A. (2009). Nasal bleeding associated with fluoxetine and risperidone interaction: A case report. Pharmacopsychiatry, 42(5), 204–205. https://doi. org/10.1055/s-0029-1220934

Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender differences in schizophrenia and firstepisode psychosis: A comprehensive literature review. Schizophrenia Research and Treatment, 2012, 1–9. https://doi.org/10.1155/2012/916198

Poznić Jesić, M., Jesić, A., Babović Filipović, J., & Zivanović, O. (2012). Extrapyramidal syndromes caused by antipsychotics. Medicinski Pregled, 65(11–12), 521– 526. https://doi.org/10.2298/mpns1212521p

Puspitasari, I. M., Sinuraya, R. K., Rahayu, C., Witriani, W., Zannah, U., Hafifah, A., Ningtyas, A. R., & Vildayanti, H. (2020). Medication profile and treatment cost estimation among outpatients with schizophrenia, bipolar disorder, depression, and anxiety disorders in indonesia. Neuropsychiatric Disease and Treatment, 16, 815–828. https://doi.org/10.2147/NDT.S240058

Rahmawati, F., Handayani, R., & Gosal, V. (2006). Kajian retrospektif interaksi obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta A retrospective study on drug interactions in Dr. Sardjito Hospital Yogyakarta. Majalah Farmasi Indonesia, 17(4), 177–183.

Sheikh, W. A. (2019). Prophylactic use of trihexyphenidyl (artane) in schizophrenia and psychosis: A critical review of literature to guide for evidence based practice in Zambia. Medical Journal of Zambia, 46(2), 133.

Siddiqui, N., Alam, M. S., Alam, O., Andalip, M., & Azad, B. (2011). Fluoxetine : Pharmacological and computational study. Webmed Central Pharmaceutical Sciences, 2(3), 1–7.

Soewadi, E., & Pramono, D. (2010). Determinan terhadap timbulnya skizofrenia pada pasien rawat jalan di Rumah Sakit Jiwa Prof . Hb Saanin Padang Sumatera Barat. Berita Kedokteran Masyarakat, 26(2), 71–80.

Spina, E., Avenoso, A., Scordo, M. G., Ancione, M., Madia, A., Gatti, G., & Perucca, E. (2002). Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology, 22(4), 419–423. https://doi.org/10.1097/00004714- 200208000-00014

Tandon, R., & Jibson, M. (2002). Extrapyramidal side effects of antipsychotic treatment: Scope of Problem and impact on outcome. Annals of Clinical Psychiatry, 14(2), 123–129. https://doi.org/10.3109/10401230209149099

World Health Organization. (2021). No Providing mental health support in humanitarian emergencies: an opportunity to integrate care in a sustainable way.

Yogeswary, K. (2014). Schizoaffective Disorder: An overview. International Journal of Clinical Psychiatry, 2(1), 11–15. https://doi.org/10.5923/j.ijcp.20140201.03

Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). Studi Penggunaan antipsikotik dan efek samping pada pasien skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. Jurnal Sains Farmasi & Klinis, 3(2), 153–164.

Zahnia, S., & Sumekar, D.W. (2016). Kajian epidemiologis skizofrenia. Majority, 5(5), 160–166.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.